Established more than 80 years ago, Garwin Gerstein & Fisher LLP (GGF) is one of the nation’s top law firms specializing in representing plaintiffs in various types of complex litigation. Since its inception, GGF has aggressively litigated on behalf of businesses, investors and consumers.
The Firm’s primary focus is on representing antitrust plaintiffs whose businesses have been adversely affected by price-fixing cartels and monopolies. With over two decades of experience in this arena, GGF has an unparalleled reputation and has been repeatedly recognized for its ground-breaking work challenging illegal agreements between brand and generic pharmaceutical companies that delay the onset of competition for prescription drugs.
Through its expertise, diligence and commitment to prosecuting cases through trial (and, if necessary, appeal), GGF has recovered over $2.5 billion on behalf of its clients:
Some notable cases that GGF has successfully resolved for its clients include:
- In Re: Suboxone Antitrust Litig.: Secured a $385 million recovery as lead counsel for a class of direct purchasers on the eve of trial in 2023.
- In re Novartis and Par Antitrust Litig. (“Exforge”): Secured a $126.85 million recovery as lead counsel for a class of direct purchasers in 2023.
- Value Drug Company v. Takeda Pharmaceuticals, U.S.A., Inc. (“Colcrys”): Secured a confidential recovery on behalf of direct purchasers mid-way through trial in 2023.
- In Re: Opana ER Antitrust Litigation: Secured a $145 million recovery as lead counsel for a class of direct purchasers on the eve of trial in 2022.
- In re: Namenda Direct Purchaser Antitrust Litig.: Secured a $750 million recovery as lead counsel for a class of direct purchasers in 2019.
- In re: Mushroom Direct Purchaser Antitrust Litig.: Secured a $45.58 million recovery as lead counsel for a class of direct purchasers in 2018-20.
- In re Lidoderm Antitrust Litig.: Secured a $166 million recovery as lead counsel on behalf of a class of direct purchasers in 2018.
- In re Aggrenox Antitrust Litig.: Secured a $146 million recovery as lead counsel for a class of direct purchasers in 2017.
- In re K-Dur Antitrust Litig.: Secured a $60.2 million recovery as lead counsel for a class of direct purchasers in 2017.
- In re Modafinil Antitrust Litig. (“Provigil”): Secured a $512 million recovery as lead counsel for a class of direct purchasers in 2015-2016.
- In re Prograf Antitrust Litig.: Secured a $98 million recovery as lead counsel for a class of direct purchasers in 2015.
- In re Neurontin Antitrust Litig.: Secured a $190 million recovery as lead counsel for a class of direct purchasers in 2014.
- In re Tricor Antitrust Litig.: Secured a $250 million recovery as lead counsel for a class of direct purchasers in 2009.
GGF consistently provides high quality representation, both in the courtroom and at the negotiation table, to achieve our clients’ litigation goals and achieve successful resolutions. If you wish to inquire further about a potential litigation matter, please Contact Us.